Last $56.47 USD
Change Today 0.00 / 0.00%
Volume 7.8M
TEVA On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 8:04 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVA) Snapshot

Open
$56.89
Previous Close
$56.47
Day High
$57.10
Day Low
$55.92
52 Week High
10/31/14 - $57.10
52 Week Low
11/5/13 - $36.26
Market Cap
48.2B
Average Volume 10 Days
4.3M
EPS TTM
--
Shares Outstanding
854.0M
EX-Date
11/13/14
P/E TM
--
Dividend
$1.28
Dividend Yield
2.42%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEVA)

teva pharmaceutical-sp adr (TEVA) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

44,945 Employees
Last Reported Date: 02/10/14
Founded in 1901

teva pharmaceutical-sp adr (TEVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEVA) Key Developments

Teva Pharmaceutical Industries Limited Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reports Impairment Charges; Revised Earnings Guidance for the Fiscal 2014

Teva Pharmaceutical Industries Limited announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenues were USD 5,058 million against USD 5,059 million a year ago. Operating income was USD 1,112 million against USD 801 million a year ago. Income before income taxes was USD 1,028 million against USD 725 million a year ago. Net income attributable to the company was USD 876 million or USD 1.02 diluted per share against USD 711 million or USD 0.84 diluted per share a year ago. Non-GAAP net income attributable to the company was USD 1,134 million or USD 1.32 diluted per share against USD 1,072 million or USD 1.27 diluted per share a year ago. Net cash provided by operating activities was USD 1,424 million against USD 444 million a year ago. The increase was mainly due to lower payments related to legal settlements in the third quarter of 2014. Non-GAAP operating income was USD 1,504 million against USD 1,330 million a year ago. For the nine months, the company reported net revenues were USD 15,104 million against USD 14,884 million a year ago. Operating income was USD 3,009 million against USD 1,089 million a year ago. Income before income taxes was USD 2,766 million against USD 749 million a year ago. Net income attributable to the company was USD 2,368 million or USD 2.76 diluted per share against USD 889 million or USD 1.04 diluted per share a year ago. Non-GAAP net income attributable to the company was USD 3,226 million or USD 3.77 diluted per share against USD 3,050 million or USD 3.58 diluted per share a year ago. Non-GAAP operating income was USD 4,236 million against USD 3,840 million a year ago. Net cash provided by operating activities was USD 3,375 million against USD 2,421 million a year ago. For the quarter, the company reported impairments, restructuring and others were USD 164 million against USD 166 million a year ago. Impairment of long-lived assets was USD 151 million against USD 131 million a year ago. For the fiscal 2014, the company now expected net revenue of USD 20.0 billion - USD 20.3 billion, gross profit of 59% to 60.5%, operating income of USD 5.65 billion - USD 5.75 billion, EPS of USD 5.00 - USD 5.10 and cash flow from operations of USD 4.5 billion compared to net revenue of USD 19.9 billion - USD 20.8 billion, gross profit of 58% to 60%, operating income of USD 5.35 billion - USD 5.65 billion, EPS of USD 4.80 - USD 5.10 and cash flow from operations of USD 3.0 billion expected previously. The company expected non-GAAP diluted EPS guidance of USD 5.00-5.10 compared to USD 4.90-5.10 as announced in July 2014.

Teva Pharmaceutical Industries Limited Declares a Cash Dividend for the Third Quarter of 2014, Payable on December 2, 2014

The Board of Directors of Teva Pharmaceutical Industries Limited, at its meeting on October 28, 2014, declared a cash dividend for the third quarter of 2014 of ILS 1.21 per share (approximately 32.1 cents according to the rate of exchange on October 28, 2014). The record date will be November 17, 2014, and the payment date will be December 2, 2014. Tax will be withheld at a rate of 15%.

Medpro Pharmaceutica (Pty) Ltd Enters into a Collaboration with Teva Pharmaceuticals (Pty) Ltd

Medpro Pharmaceutica (Pty) Ltd. announced that it has entered into a collaboration with Teva Pharmaceuticals (Pty) Ltd. The collaboration is restricted to the territory of South Africa. The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva's broad pharmaceutical product portfolio in South Africa. The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva's broad pharmaceutical product portfolio in South Africa. This collaboration is highly complementary and aligns strongly with philosophy of providing South Africans with access to a broader range of affordable medicines.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $56.47 USD 0.00

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.59 USD +0.10
AbbVie Inc $63.46 USD +2.28
Actavis plc $242.74 USD -0.47
Baxter International Inc $70.14 USD +0.08
Eli Lilly & Co $66.33 USD -0.47
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings 18.6x
Price/Sales 2.3x
Price/Book 2.0x
Price/Cash Flow 20.8x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.